💊
Kymriah
tisagenlecleucel
Leucemia-linfoma de células B precursoras; Linfoma de grandes células B, difuso
✅ Autorizado
Terapia avançada
✅
Nenhum alerta ativo
Este medicamento não apresenta escassez contínua, cartas de segurança ou recolhimentos.
Para que serve
Kymriah is indicated for the treatment of: • Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse. • Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy. • Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.
⚠️ Segurança do paciente
No
Página oficial da EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah